|Bid||57.00 x 1800|
|Ask||65.00 x 1800|
|Day's Range||56.94 - 65.03|
|52 Week Range||19.35 - 72.94|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.40|
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced it is initiating an open-label extension study in the United States for its Phase 2/3 GAIN Trial of COR388 in subjects with mild to moderate Alzheimer’s disease (AD). Additionally, the GAIN Trial Data Monitoring Committee recently completed its first planned safety review and recommended continuation of the study as planned.
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Timing is everything: Here's a look at the big gap in returns for public and private investors in the best performing new Bay Area stocks from last year.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.
(Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at email@example.comTo contact the editors responsible for this story: Brad Olesen at firstname.lastname@example.org, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the "gingipain hypothesis" for Alzheimer’s disease (AD) to the significance of the APOE gene as a major risk factor for the disease. Michael Detke, M.D., Ph.D., the company’s chief medical officer, detailed the results in an oral presentation (abstract OC28) at the 2019 Clinical Trials in Alzheimer’s Disease (CTAD) meeting, which is being held December 4-7, 2019 in San Diego.
Biogen shares fell 2.6% after an analyst scoffed at the possibility of a Food and Drug Administration approval for the company's experimental Alzheimer's disease treatment. "There are so many reasons we think aducanumab is getting rejected, our word count restrictions don't allow us to put them all here," Baird analyst Brian Skorney wrote in a Dec. 2 note. Skorney's primary argument is that he believes data from the most recent clinical trial doesn't make for a compelling case to take to the FDA. Earlier this year, Biogen's stock tumbled to a three-year low after the company said it would stop trials for the therapy, prompting Mizuho analyst Salim Syed to say "aducanumab is dead, and we'd argue so is the beta-amyloid hypothesis." But then in October Biogen announced plans to pursue FDA approval following discussions with the regulator. The biopharmaceutical company has said it will release additional clinical trial information about aducanumab on Dec. 5. Separately, shares of Cortexyme Inc. , which is also developing an Alzheimer's treatment, jumped in morning trading, by 20%. Shares of Biogen have fallen about 3% year-to-date, compared to the S&P 500 , which has gained about 24%.
Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 2:00 p.m. EST / 11:00 a.m. PST in Boston.
— Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer’s disease, continues to advance in Phase 2/3 GAIN clinical trial
The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.
Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that its lead investigational medicine, COR388, will be the subject of an oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2019. The company will also host a lunch briefing on the preclinical and clinical data supporting COR388’s mechanism of action, as well as its evaluation in the ongoing Phase 2/3 GAIN trial.
The big shareholder groups in Cortexyme, Inc. (NASDAQ:CRTX) have power over the company. Generally speaking, as a...